

John Koreth

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11736626/john-koreth-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

7,989
citations

46
h-index

89
g-index

138
ext. papers

9,415
ext. citations

5
avg, IF

5.22
L-index

#	Paper	IF	Citations
130	Interleukin-2 and regulatory T cells in graft-versus-host disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2055-66	59.2	787
129	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2349-61	27.4	612
128	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016 , 375, 143-53	59.2	365
127	Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007 , 109, 4586-8	2.2	349
126	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. <i>Science Translational Medicine</i> , 2013 , 5, 179ra43	17.5	312
125	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2691-8	2.2	295
124	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009 , 113, 3865-74	2.2	236
123	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
122	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1598-1605	2.2	208
121	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2662-70	2.2	203
120	Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 984-99	4.7	196
119	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1479-93	15.9	175
118	High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 183-96	4.7	168
117	Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. <i>Blood</i> , 2007 , 109, 3108-14	2.2	163
116	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014 , 123, 3988-98	2.2	144
115	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. <i>Blood</i> , 2010 , 116, 1839-48	2.2	141
114	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008 , 112, 4425-31	2.2	139

113	Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 565-74	4.7	136
112	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4867-76	15.9	132
111	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016 , 128, 130-7	2.2	132
110	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007 , 110, 490-500	2.2	119
109	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017 , 129, 2186-2197	2.2	109
108	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016 , 127, 646-57	2.2	109
107	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (MM1-11-1203). <i>Lancet Haematology</i> , 2019 , e132-43	14.6	101
106	Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 15825-30	11.5	94
105	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016 , 127, 2144-54	2.2	94
104	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013 , 122, 1510-7	2.2	93
103	Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5767-74	2.2	92
102	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1155-66	4.7	87
101	Low-dose IL-2 selectively activates subsets of CD4 Tregs and NK cells. <i>JCI Insight</i> , 2016 , 1, e89278	9.9	87
100	Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 852-60	4.7	80
99	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016 , 128, 1013-7	2.2	77
98	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015 , 125, 4085-94	2.2	76
97	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016 , 127, 2489-97	2.2	71
96	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1343-59	4.7	69

95	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1180-5	4.7	69
94	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017 , 129, 22-29	2.2	68
93	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1783-9	4.7	68
92	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 792-800	4.7	68
91	Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018 , 131, 1372-1379	2.2	59
90	Does iron overload really matter in stem cell transplantation?. <i>American Journal of Hematology</i> , 2012 , 87, 569-72	7.1	56
89	Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1713-8	4.7	55
88	Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1196-204	4.7	51
87	A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 28-35	4.7	48
86	Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 211-5	4.7	47
85	Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of	2.2	46
84	Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Research (CIBMTR) Investigators' "A Study of the Addition of Sirolimus to the Graft-versus-Host Disease Prophylaxis Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation for Lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016 , 173, 96-104	4.5	43
83	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017 , 2,	9.9	40
82	Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in <i>C. elegans</i> and human cancer cells. <i>Nature Communications</i> , 2015 , 6, 5906	17.4	39
81	Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 873-80	4.7	38
80	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4.7	37
79	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 118, 5021-30	2.2	34
78	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016 , 122, 3005-3014	6.4	32

77	Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 575-83	4.7	30
76	Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 668-75	4.7	29
75	Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2010 , 95, 364-6	6.6	29
74	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 137-144	4.7	27
73	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
72	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016 , 101, 499-505	6.6	26
71	Cell-cycle control in <i>Caenorhabditis elegans</i> : how the worm moves from G1 to S. <i>Oncogene</i> , 2005 , 24, 2756-64	9.2	24
70	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2199-2204	7.8	24
69	Current and future approaches for control of graft-versus-host disease. <i>Expert Review of Hematology</i> , 2008 , 1, 111	2.8	23
68	Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2017 , 65, 510-513	11.6	20
67	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 910-8	4.7	19
66	The role of regulatory T cells in graft-versus-host disease management. <i>Expert Review of Hematology</i> , 2020 , 13, 141-154	2.8	19
65	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019 , 3, 2550-2561	7.8	19
64	Venous thromboembolism is associated with graft-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017 , 102, 1185-1191	6.6	18
63	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1251-1259	6.6	17
62	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017 , 1, 2269-2279	7.8	15
61	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 969-979	7.8	15
60	Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2015 , 22, 116-22	3.3	14

59	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 1499-508	6.6	14
58	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019 , 133, 94-99	2.2	14
57	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017 , 19, 272-284	4.8	13
56	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 2889-2899	2.2	13
55	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015 , 100, 1222-7	6.6	13
54	Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 421-8	4.7	13
53	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
52	Tregs, HSCT, and acute GVHD: up close and personal. <i>Blood</i> , 2013 , 122, 1690-1	2.2	12
51	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 984-994	7.8	12
50	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021 , 5, 861-871	7.8	11
49	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021 , 137, 3212-3217	2.2	9
48	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2084-2091	4.7	8
47	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019 , 19, 1820-1830	8.7	8
46	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020 , 135, 28-40	2.2	8
45	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020 , 4, 1881-1893	7.8	7
44	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 529-539	4.7	7
43	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
42	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7

41	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 860-860	2.2	5
40	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1006-1012	4.4	5
39	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 830-830	2.2	3
38	A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. <i>Haematologica</i> , 2020 , 105, e379-e381	6.6	2
37	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 595-595	2.2	2
36	The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. <i>Blood</i> , 2013 , 122, 704-704	2.2	2
35	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021 , 35, 1166-1175	10.7	2
34	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006 , 108, 2929-2929	2.2	1
33	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006 , 108, 3680-3680	2.2	1
32	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007 , 110, 2016-2016	2.2	1
31	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. <i>Blood</i> , 2007 , 110, 3046-3046	2.2	1
30	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013 , 122, 695-695	2.2	1
29	Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates. <i>Blood</i> , 2014 , 124, 41-41	2.2	1
28	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 986-986	2.2	1
27	Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2014 , 124, 2496-2496	2.2	1
26	Hematopoietic Cell Transplants for Myelodysplastic Syndromes328-338		
25	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009 , 27, e139-e140	2.2	
24	Multiple myeloma in a 50-year-old with an HLA-identical sibling. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1247-8	4.7	

- 23 Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. *Blood*, **2020**, 136, 10-11 2.2
- 22 Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2020**, 136, 2-3 2.2
- 21 Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. *Blood*, **2021**, 138, 2891-2891 2.2
- 20 Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. *Blood*, **2006**, 108, 757-757 2.2
- 19 Non-Myeloablative Allogeneic Transplantation for Hodgkin's and Non-Hodgkin's Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. *Blood*, **2007**, 110, 3041-3041^{2,2}
- 18 Stem Cell Transplantation in Multiple **2008**, 149-166
- 17 Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. *Blood*, **2014**, 124, 662-662 2.2
- 16 Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. *Blood*, **2014**, 124, 3961-3961 2.2
- 15 Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells. *Blood*, **2014**, 124, 1414-1414 2.2
- 14 Immunosuppression Taper to Induce Graft-Versus-Tumor Activity As the Sole Therapy for Early Relapse after Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2014**, 124, 2504-2504^{2,2}
- 13 Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin. *Blood*, **2014**, 124, 3862-3862 2.2
- 12 Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease. *Blood*, **2015**, 126, 3133-3133 2.2
- 11 Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. *Blood*, **2016**, 128, 508-508 2.2
- 10 BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 3425-3425 2.2
- 9 Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. *Blood*, **2016**, 128, 667-667 2.2
- 8 Does Iron Overload Really Matter in Stem Cell Transplantation?. *Blood*, **2011**, 118, 3029-3029 2.2
- 7 A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. *Blood*, **2011**, 118, 327-327 2.2
- 6 RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. *Blood*, **2011**, 118, 4134-4134 2.2

- 5 Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). *Blood* , **2012**, 120, 1892-1892 2.2
- 4 Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2012**, 120, 4136-4136 2.2
- 3 Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. *Blood*, **2012**, 120, 3069-3069 2.2
- 2 Age Does Not Predict Outcomes For Elderly Patients With Myelodysplastic Syndromes Undergoing Hematopoietic Stem Cell Transplantation With Reduced-Intensity Conditioning. *Blood*, **2013**, 122, 2147-2147 2.2
- 1 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults **2018**, 970-980.e4